Comparison of metformin, gliclazide MR and rosiglitazone in monotherapy and in combination for type 2 diabetes.

@article{Vilar2010ComparisonOM,
  title={Comparison of metformin, gliclazide MR and rosiglitazone in monotherapy and in combination for type 2 diabetes.},
  author={Lucio Vilar and Viviane Canadas and Maria Juliana Arruda and Carla M. Arahata and Rodrigo Agra and Lisete Pontes and Larissa Montenegro and Clarice Freitas Vilar and Lidiane Moura e Silva and Jos{\'e} Luciano Albuquerque and Amaro Gusm{\~a}o},
  journal={Arquivos brasileiros de endocrinologia e metabologia},
  year={2010},
  volume={54 3},
  pages={311-8}
}
OBJECTIVE To compare the efficacy and tolerability of metformin, rosiglitazone and gliclazide MR as monotherapy and in combination in the treatment of type 2 diabetes. SUBJECTS AND METHODS 250 patients treated with oral antidiabetic agents for at least 24 weeks in monotherapy or in combination therapy were included in this retrospective study. RESULTS As monotherapy the reduction of fasting plasma glucose (FPG), postprandial glycemia (PPG) and HbA1c was similar with the three drugs after 24… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 45 references

Type 2 diabetes mellitus: what is the optimal treatment regimen?

The American journal of medicine • 2004
View 4 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…